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Abstract 29 
Chlamydia trachomatis continues to be the most commonly reported sexually 30 
transmitted bacterial infection in many countries with more than 100 million new 31 
cases estimated annually. These acute infections translate into significant 32 
downstream health care costs, particularly for women, where complications can 33 
include pelvic inflammatory disease and other disease sequelae such as tubal factor 34 
infertility.  Despite years of research, the immunological mechanisms responsible for 35 
protective immunity versus immunopathology are still not well understood, although it 36 
is widely accepted that T cell driven IFN-g and Th17 responses are critical for 37 
clearing infection. While antibodies are able to neutralize infections in vitro, alone 38 
they are not protective, indicating that any successful vaccine will need to elicit both 39 
arms of the immune response. In recent years, there has been an expansion in the 40 
number and types of antigens that have been evaluated as vaccines, and combined 41 
with the new array of mucosal adjuvants, this aspect of chlamydial vaccinology is 42 
showing promise. Most recently, the opportunities to develop successful vaccines 43 
have been given a significant boost with the development of a genetic transformation 44 
system for Chlamydia, as well as the identification of the key role of the chlamydial 45 
plasmid in virulence. While still remaining a major challenge, the development of a 46 
successful C.trachomatis vaccine is starting to look more likely.   47 
 48 
  49 
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Chlamydial infection and disease 50 
Tubal factor infertility (TFI) is a globally significant public health problem caused by 51 
several microbial agents, including untreated genital infections with Chlamydia 52 
trachomatis [1]. C.trachomatis remains the most commonly reported infectious 53 
disease in many countries. It is estimated that in 2008, there were 106 million new 54 
cases of C.trachomatis in adults (15 – 49 years) with an estimated 100 million people 55 
infected at any one time [2]. These acute infections translate into significant 56 
downstream health costs with an estimated 714,000 disability-adjusted life years 57 
(DALYs) lost as a result of C.trachomatis infections [3]. In the United States alone, 58 
direct medical costs for chlamydial infections exceed US$500 million annually, 59 
excluding costs for screening programs and indirect costs like lost productivity [4]. 60 
  61 
The largest burden of disease from C.trachomatis is in women where untreated 62 
genital infections can lead to pelvic inflammatory disease (PID) and, in some cases,  63 
sequelae including TFI (18% cases following symptomatic PID) resulting from 64 
fallopian tube scarring [1,5]. Infections during pregnancy may cause premature labor 65 
and may also cause neonates to develop conjunctivitis or pneumonia [6]. The high 66 
prevalence of infections among women of child-bearing age exposes an estimated 67 
100,000 neonates to Chlamydia annually in the United States [7]. In men, 68 
C.trachomatis is the most commonly reported sexually transmitted infection (STI) 69 
and the leading cause of non-gonococcal (non-specific) urethritis [8, 9]. Following 70 
upper genital tract ascension, C.trachomatis may cause acute infectious epididymitis 71 
[10]; C.trachomatis infections have been reported in 40-85% men with epididymitis 72 
[11]. However, up to 90% of chlamydial infections in females and 50% in males are 73 
asymptomatic. This indicates that the incidence of reported chlamydial infections 74 
from surveillance data is likely a gross global under-estimate and that screening of 75 
asymptomatics would detect even more infections [12-14]. 76 
 77 
The need for chlamydial vaccines 78 
Potential interventions for reducing the incidence of infection and disease sequelae 79 
associated with Chlamydia include; (i) educational-based behaviour change 80 
promotion (e.g. increasing condom use or reducing partner numbers); (ii) increased 81 
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screening, treatment and contact tracing / partner notification; (iii) the development of 82 
new biomedical prevention or therapeutic technologies (such as vaccines) (see 83 
review by Gottlieb et al. in this issue) [15]. However, it is not feasible to implement 84 
behaviour change campaigns to a sufficient scale and efficacy to result in population-85 
level impacts.  86 
 87 
Since a Chlamydia vaccine is not currently available, the only viable public health 88 
strategy is the scale-up of screening for chlamydial infection coupled with the 89 
administration of a course of antibiotics and counselling or follow up for partner 90 
notification or contact tracing and also rescreening. Chlamydia screening may be 91 
cost-effective and partner notification is an effective adjunct, with treatment using 92 
azithromycin evaluated to be cost-effective [16]. Screening is generally considered to 93 
be acceptable and feasible among most target populations [17,18]. However, uptake 94 
is likely to be the limiting factor, even in ideal study conditions with specific invitations 95 
for screening, with less than 45% of populations at risk of Chlamydia being routinely 96 
screened [18-22]. Modelling studies have indicated that at least 45-60% screening 97 
levels are required to have noticeable epidemiological impacts [22-25] and these 98 
coverage levels, or greater, must be sustained at least annually, indefinitely. It is 99 
unlikely that the coverage and frequency of screening and treatment interventions 100 
could reach sufficiently high levels to result in epidemic declines approaching 101 
elimination.  Not only are there issues of limited coverage and frequency which 102 
reduces effectiveness, but treatment efficacy is not perfect [26-28], drug resistance is 103 
possible, re-infection is extremely common,[29,30] and there is no end to the need to 104 
continue regular rescreening.  105 
 106 
In addition, despite continued improvements in diagnostic and screening procedures 107 
for Chlamydia, and although antibiotics like azithromycin are available to treat 108 
infections, notifications of infections continues to increase. Antibiotic treatment of 109 
individuals may also increase susceptibility to re-infection, which is most likely due to 110 
interrupting the natural course of protective chlamydial immunity [31]. Recently, data 111 
from an in vivo study reported that not only were T-helper (Th)1 immune responses 112 
against C.trachomatis in individual women slow to develop, but that these responses 113 
were also altered by treatment with ceftriaxone and azithromycin [32]. Taken 114 
together, these facts suggest that the current main line of defence against chlamydial 115 
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infections (ie. administration of antibiotics following screening) is far from fully 116 
effective on a population level, and hence a vaccine may be the only way to address 117 
this problem.  In addition, the strategy of control programs based on screening, 118 
treatment and contact tracing is extremely costly and requires substantial societal 119 
infrastructure. This makes this approach impractical for the developing world, where 120 
the burden of disease is the greatest. 121 
 122 
Thus, development of a safe and effective vaccine is the ultimate goal in the control 123 
of Chlamydia. The relative uptake of a vaccine versus screening is difficult to 124 
quantify at present, but it is likely that a vaccine would be more widely accepted as 125 
evidenced by uptake of the HPV vaccine in settings where it is available and 126 
supported [33,34]. Costing of a Chlamydia vaccine is not possible at this stage. 127 
However, based on experience from other vaccines, prices could be negotiated to 128 
levels that are cost-effective. The most important issue of all is whether a vaccine 129 
actually works, that is, has high efficacy and prevents acquisition of infection, 130 
transmitting infection or developing disease. This can only be ascertained through 131 
clinical research after the development of suitable vaccine candidate(s). With no 132 
other long-term strategy available, investment in Chlamydia vaccine design, 133 
development and evaluation is the most appropriate way forward.  134 
 135 
Our objectives in this review are to discuss infections and diseases of the genital 136 
tract caused by C.trachomatis with a focus on the complexities and challenges of 137 
chlamydial vaccine development. These include considerations such as how to; (i) 138 
better understand the range of immunological responses elicited by / to this 139 
organism, and therefore to subsequently define effective vaccine antigens and 140 
suitable biomarkers of protection, (ii) interpret the results obtained from animal 141 
models of infection, (iii) optimally choose, combine, and present vaccine antigens 142 
(surface and/or internal antigens, mucosal adjuvants) and, (iv) interpret mathematical 143 
models to define effective vaccine goals for preventing acquisition of infection, 144 
interrupting transmission, and/or preventing tubal disease.  145 
 146 
The immunological challenges 147 
 148 
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C.trachomatis is a small (0.5μm) bacterium that elicits inflammatory cytokine 149 
responses following infections of epithelial cells and macrophages. The complex, 150 
two-stage developmental cycle of Chlamydia is described in Figure 1 (a). The 151 
extracellular infectious elementary bodies (EB) avoid lysosomal fusion to survive and 152 
differentiate into metabolically active reticulate bodies (RB) [35,36 and reviewed in 153 
[37]). The chlamydial RBs then replicate by around 500-fold, and subsequently re-154 
differentiate into EBs inside a membrane-bound parasitophorous vacuole (“inclusion”) 155 
eventually being released by extrusion and/or cytolysis after 40-72 hours to infect 156 
new cells or hosts [38]. Chlamydia can also enter a persistent growth state if 157 
exposed to molecular and cellular stresses such as inadequate antibiotic treatment 158 
or host cytokines, particularly IFN-g. The persistent form is characterised by large 159 
viable, non-infectious aberrant bodies (AB) (reviewed in [39]). In this form 160 
chlamydiae are refractory to killing by azithromycin [40] and this may allow for in vivo 161 
persistence of the pathogen. 162 
 163 
In humans, immune responses to resolve C.trachomatis genital tract infections  164 
apparently develop over months to years. In uncomplicated, productive chlamydial 165 
genital infections, a myriad of host immune responses are elicited that include innate 166 
and adaptive immune mechanisms acting to clear infection and to resist re-infection  167 
[41](summarized in Figure 1 (b) and reviewed in [42]). Chlamydia can, however, also 168 
grow inside macrophages and dendritic cells (DCs) to produce persistently-infected 169 
cells (reviewed in [43]). In both productively and persistently-infected chlamydial host 170 
cells inflammatory cytokines are released that may induce and sustain tissue 171 
damage and host inflammatory responses [44-46].  Chlamydial infections induce 172 
both innate and adaptive cascades but it is acknowledged that the key effectors for 173 
both protection and pathology pathways are IFN-g and interleukin 17. While high 174 
levels of IFN-g are chlamydicidal, low levels can actually result in persistence and 175 
this may lead to worse pathology. This highlights the critical nature of the correct 176 
balance between mechanisms of protection (as will be required for effective vaccines) 177 
versus triggering adverse pathology. 178 
 179 
During active primary infections in women, serum and genital mucosal IgA and IgG 180 
antibodies to chlamydial EBs and specific chlamydial proteins including heat-shock 181 
(HSP) and plasmid proteins, are usually detected [47]. In patients with current genital 182 
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infections, the predominant serum responses are maintained for at least 6 months 183 
and are mainly IgG1 and IgG3 antibodies [48]. Local IgA antibodies correlate with 184 
reduced shedding of the chlamydial organism from the genital tract [49].  However, 185 
high titres of local IgA antibodies do not correlate with resolution of infection, but can 186 
act as markers of prior chlamydial infections.   The major role antibodies appear to 187 
play in clearance of infection is in the enhancement of Th1 activation with CD4+ T 188 
cells secreting IFN-g correlating primarily with the resolution of infections.  Of note 189 
however, is the fact that CD4+T cell immunity is slow to develop and therefore 190 
infections frequently are repeated and chronic.  191 
 192 
Chronic infections are characterised by genital tract inflammation and infiltration of 193 
innate immune cells along with inflammatory mediators to the genital mucosa [for a 194 
summary of chemokines and cytokines produced during chlamydial infections see 195 
[50].  High levels of IFN-g are found in the cervix and fallopian tubes in women with 196 
C.trachomatis genital tract infections [51]. IFN-g delays the developmental cycle of 197 
Chlamydia which may result in persistent and in-apparent infections that might 198 
contribute to promoting inflammatory damage of the genital tract [52].  199 
 200 
The inability of immune responses to clear infections and prevent ascension of 201 
bacteria to the oviduct is also due to several strategies used by Chlamydia to evade 202 
the immune system [53]. Mechanisms used by Chlamydia to subvert host innate 203 
immune responses include blocking transcription factor NF-kB activation directly 204 
through the proteolysis of the p65/RelA subunit of NF-kB [54]. Virulence associated 205 
genes of Chlamydia have also recently been reported to be transcriptionally 206 
regulated by  the Pgp4 protein encoded by the highly conserved 7.5kB cryptic 207 
plasmid of Chlamydia trachomatis [55].These genes include pgp3 that encodes a 208 
protein to which immune responses are elicited in patients with C.trachomatis 209 
infection  (see Table 1) . Chlamydia also inhibit IFN-g-inducible major 210 
histocompatibility complex (MHC) class II expression expression [56], down-regulate 211 
MHC class I heavy chain (HC) presentation  [57], and in human endocervical cells 212 
this is mediated by direct and indirect (soluble) factors [58]. The multiple potential 213 
mechanisms used by Chlamydia dampen immune responses have recently been 214 
well summarized [50]. 215 
 216 
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The consequent development of chlamydial disease following genital tract infections 217 
in humans is multifactorial and involves not only chlamydial factors such as virulence 218 
via different C.trachomatis strains but also host and environmental factors. For 219 
example, a recent  prospective study of African-American women with clinically 220 
suspected mild to moderate cases of PID showed that gene polymorphisms in 221 
several innate immune receptors (including Toll-like receptors [TLR] 1 and 4) were 222 
associated with increased genital tract C.trachomatis infections [59].  The female 223 
genital tract is also a unique mucosal site in that it is influenced by fluctuating 224 
hormone levels and the polymicrobial environment. Hormone changes directly affect 225 
cell type and indirectly affect both the innate and adaptive immune responses to 226 
chlamydial genital infections [60]. Changes in bacterial flora and genital tract 227 
inflammation are both suggested cofactors for persistence of Chlamydia at this site 228 
and affect vaginal pH, which may be associated with the risk of acquiring 229 
C.trachomatis infection [61] [62]. The reproductive tract microbiome, sex hormones 230 
and immune responses are challenges for development of vaccines against genital 231 
tract pathogens and are discussed in detail in a paper in the current issue [63]. 232 
 233 
The value of animal models 234 
What the mouse model has, and has not, told us 235 
While animal models are useful and convenient, they must provide data about 236 
vaccination that will eventually be transferrable to the human situation.  In the case 237 
of chlamydial STIs, the mouse model is the most widely used model for infection, 238 
pathogenesis and vaccine studies. Primary genital tract infections of female mice 239 
with elementary bodies of the mouse-adapted C.muridarum strain are enough to 240 
cause tubal dilatation since a consistent observation is the development of 241 
hydrosalpinx shortly (1-2 days) after initial chlamydial infection in this model [64]. 242 
Hydrosalpinx characteristically is also associated with tubal factor infertility in 243 
humans [65], making this model useful in this respect. However this observation in 244 
the murine model contrasts with documented evidence from the guinea pig C.caviae 245 
model of a primary genital tract infection in which chronic oviduct pathology was 246 
reported in only 12% of the animals, even though almost 80% were infected[66]. In 247 
humans, long-term chronic infections can develop after the primary infection [67] and 248 
the risk of pathology is known to increase after repeated infections [5]. Thus the 249 
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guinea pig model, with observed pathology following primary chlamydial infections 250 
and anatomy, and physiology similar to the human female genital tract, more closely 251 
resembles human chlamydial disease than the murine model. 252 
Choosing the most informative animal model to investigate CD4+ effector cell 253 
subsets elicited to combat C.trachomatis genital tract infections in humans will 254 
require prudence. Rather than using the mouse strain, C.muridarum, several groups 255 
have used human C.trachomatis and shown that intravaginal inoculation of mice with 256 
this  strain results a mild, self-limiting, lower reproductive tract infection with minimal 257 
ascension to the upper genital tract [68]. The eradication of C.trachomatis in the 258 
mouse is reportedly independent of indoleamine 2, 3-dioxygenase (IDO) [69] and yet 259 
this is a principle mechanism of protection against C.trachomatis infection in human 260 
cells, where IDO-catalyzed tryptophan degradation starves the chlamydial inclusion 261 
of this amino acid [70]. Nevertheless, using this murine model, it has been 262 
established that to resolve genital chlamydial infection an influx of IFN-g-producing 263 
CD4+ Th1 cells is required [71,72] along with numerous host factors including matrix 264 
metalloproteinases (MMPs) such as MMP9 [73].  265 
The host response to chlamydial infection is also proposed to directly damage 266 
mucosal tissues of the female genital tract. One hypothesis states that infected 267 
epithelial cells secreting pro-inflammatory cytokines/chemokines to initiate 268 
pathogenesis (the cellular paradigm) whilst the second (immunological paradigm), as 269 
mentioned earlier in this paper, proposes that T-cell responses that are essential to 270 
resolve infection can also cause tissue damage [46, 53,74]. The immunological 271 
paradigm for pathogenesis is supported by observations from both the guinea pig [75] 272 
and the non-human primate (NHP) [76] models of genital infection in which repeated 273 
oviduct infections cause rapid infiltration of CD4 and CD8 T cells to the infection site. 274 
The value of the non-human primate model 275 
Despite the fact that the majority of vaccine studies have been undertaken using the 276 
mouse model, there has also been a long history of non-human primate (NHP) 277 
models used in the study of chlamydial disease (dating back to 1936). The value of 278 
using NHPs as a model lies in their evolutionary closeness to Homo sapiens. NHPs 279 
have been particularly effective in the study of tubal pathology (pelvic inflammatory 280 
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disease) (reviewed in [77]). However, the use of NHPs in vaccine evaluation has 281 
been less effective. Currently there are no studies that have evaluated the protective 282 
efficacy of a vaccine targeting urogenital infections (the closest simply measuring 283 
immune responses at multiple mucosal sites following immunisation [78]). 284 
Nevertheless, recent studies have shown the NHP model to be a promising platform 285 
for the evaluation of trachoma vaccines [79, 80], including one recent study showing 286 
promise with a live, plasmid-free, attenuated vaccine [81]. Although NHP models 287 
offer a biological system much more comparable to that of the human they are not 288 
without limitations. Currently there is no known natural NHP strain of Chlamydia. 289 
High inoculum doses of C.trachomatis are required to establish an infection (and 290 
pathology) [81, 82], as well as the fact that differences in immune responses and 291 
disease states have been found with different infecting serovars [82,83], as well as 292 
the NHP species used [78]. Therefore, for the successful use of NHPs in vaccine 293 
evaluation, it is essential to define the immunological mechanisms behind clearance 294 
of the human strains, and to compare that to the paradigm associated with clearance 295 
in humans. If this can be done, then NHP models will indeed be valuable in the 296 
development of C.trachomatis vaccines for humans.  297 
Update on current vaccine progress 298 
Given the global importance of C.trachomatis STIs, and the strong case for a 299 
vaccine to curb increasing infection rates, how are we progressing towards the goal 300 
of an effective vaccine? The critical questions to ask are, (i) why doesn’t natural 301 
infection result in strong protection? and (ii) how successful have past vaccination 302 
attempts been, or at least, what can we learn from these trials? The answers to both 303 
of these questions are actually quite promising. 304 
Natural infection can induce partial immunity but may also result in adverse 305 
pathology : Natural infection does lead to a degree of protection. In the mouse 306 
model this is certainly the case, with animals given a live infection being very solidly 307 
protected against a second (challenge) infection in that they shed very low levels of 308 
organisms [64]. A similar effect was observed in the early trachoma vaccine trials in 309 
which inactivated C.trachomatis organisms offered some degree of protection [84]. 310 
Indeed, there are some valuable lessons that can be learned from the early 311 
trachoma trials as well as more recent studies of ocular C.trachomatis natural 312 
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infections (reviewed by Mabey et al., 85] The early trachoma vaccine trials in 313 
countries such as Saudi Arabia, Taiwan, The Gambia, India and Ethiopia, showed 314 
that it was possible to induce short term immunity to ocular infection, and also to 315 
reduce the incidence of inflammatory trachoma, by administering vaccines based on 316 
killed or live whole organisms. The problem though is that these whole organism 317 
vaccines, whether infectious chlamydial elementary bodies or whole inactivated 318 
organisms, contain both protective as well as deleterious antigens. In the case of the 319 
early trachoma vaccine trials, the approach led to some enhanced immunopathology 320 
in some of the vaccinees [84]. This same enhanced immunopathology effect is 321 
observed in mouse trials in animals given a live vaccine and then challenged with 322 
live organisms at a later date [86]. Recent studies have also suggested that some 323 
women, infected naturally at the genital tract site, can mount a level of immunity 324 
against subsequent infections [87]. Indeed, these observations are extremely 325 
encouraging for the development of effective vaccines as these individuals can be 326 
utilised to identify bio-profiles of protection (for humans) and then vaccine trials can 327 
attempt to induce these protective bio-profiles. The second issue, which is often not 328 
discussed, is that any protection is usually only short lived, with most vaccine trials 329 
only evaluating protection up to 4 weeks post vaccination. 330 
Identification and choice of vaccine target antigens : As a result of the issues 331 
surrounding crude, whole chlamydial vaccines, all efforts now involve the use of 332 
purified / cloned individual chlamydial antigens and virtually all of these studies have 333 
been conducted in the C.muridarum – mouse model.  Indeed, while early vaccine 334 
efforts focussed very much on MOMP, and other surface antigens (eg Omp2), the 335 
past 5 years has seen a significant expansion in the number and type of antigens 336 
evaluated, including CPAF, PmpD, PmpG, CopN, IncA, NrdB and Pgp3 (many of 337 
which are intracellular proteins or at least not outer membrane proteins), in addition 338 
to the earlier favourites of MOMP, Omp2 and Hsp60 [42] (see Table 1 for a list of all 339 
antigens that have been shown to induce an immune response following genital tract 340 
infection). Figure 1 (a) provides an overview of the chlamydial developmental cycle, 341 
including points of attack as well as vaccine candidates that have, or could be, tested 342 
for each of these stages. Progress towards identifying the “holy grail” vaccine 343 
antigen has been relatively slow, with most new antigens evaluated only providing 344 
very modest, stepwise improvement in protection against live challenge. The search 345 
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for the best protective antigens though has become much more sophisticated 346 
recently, with groups directly identifying effective T cell antigens [88]. Brunham and 347 
colleagues are using an immunoproteomic screening approach to identify chlamydial 348 
antigens, or more correctly the actual T cell peptides, that are presented by 349 
C.muridarum-infected dendritic cells in the mouse model. Using this approach they 350 
have recently identified 13 Chlamydia peptides derived from eight novel epitopes 351 
presented by MHC class II molecules from bone marrow derived dendritic cells 352 
infected with Chlamydia. While some of the targets are new (RplF, FabG, AasF, 353 
ClpP-1, Gap, PmpE), interestingly, some overlap with previously identified antigens 354 
(PmpG). 355 
Will a single antigen be sufficient or are antigen combinations required : In 356 
addition to searching for the most highly protective vaccine candidate antigen, 357 
several groups now believe that a combination of antigens will be required. There 358 
are several lines of thought in compiling combination antigen vaccines. 359 
C.trachomatis has multiple serovars and to cover the antigenic diversity that exists 360 
across the main genital tract strains (D to K) will require the vaccine to contain 361 
epitopes or whole proteins for each strain; this is certainly the case for a MOMP-362 
based vaccine and will probably also be the case for other variable proteins, such as 363 
the Pmps. A more sophisticated strategy that is evolving, is to target several different 364 
but key proteins in the chlamydial repertoire. Chlamydia has evolved over its long 365 
history to have multiple mechanisms of infecting and controlling its host and hence a 366 
vaccine that does not rely on a single target has the best chance of success. To this 367 
end, the concept of targeting several surface proteins (such as MOMP, Pmps, Incs) 368 
as well as some internal or secreted regulatory proteins (such as CPAF, NrdB) has 369 
significant merit (Figure 1 (a) summarizes the antigens related to each stage of the 370 
chlamydial developmental cycle, and Table 2 shows how these might be combined 371 
effectively in multi-antigen vaccines). In addition, specifically targeting antigens that 372 
are more highly expressed in the persistent or chronic phase of infection / disease, 373 
has considerable merit.  While the major goal of a chlamydial vaccine is to prevent 374 
infection in naive individuals, it may not be possible to screen all vaccinees to ensure 375 
they are negative prior to vaccination.  In addition, if sterilizing immunity is difficult or 376 
impossible to achieve, then including persistence phase antigens in a vaccine would 377 
have significant merit. Such multi-target vaccines are well within the reach of current 378 
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technologies and clearly are successful with other infectious disease vaccines, such 379 
as meningococcal disease vaccines. 380 
A key role for adjuvants : All candidate antigens though require effective adjuvants 381 
and the optimal delivery mechanism to be an effective vaccine. The challenge with a 382 
C.trachomatis STI vaccine is that the vaccine-adjuvant combination must elicit the 383 
correct balance of Th2 (neutralising antibodies) and Th1 (IFN-g and Th17 cytokines) 384 
responses and it must do this at the required mucosal sites (female genital tract). 385 
Thanks to recent progress in vaccinology and immunology more broadly, the range 386 
of adjuvants that are now available, and well advanced in human safety trials [89] is 387 
rapidly increasing and some promising results with C.trachomatis vaccines are 388 
emerging. The range of adjuvants and delivery systems that have been evaluated 389 
with C.trachomatis vaccines include immunostimulating complexes [88,90], 390 
detergent/surfactant-based adjuvants [91], live viral vectors [92], Vibrio cholerae 391 
ghosts [93], liposomes [[94], CpG and their more recently developed, safe 392 
derivatives [88] and cytokines. 393 
Vaccines against infection or downstream pathology : One challenge for 394 
chlamydial vaccine development is whether it should (i) primarily aim to significantly 395 
reduce or even eliminate the infection, or (ii) should also, or perhaps only, aim to 396 
reduce or eliminate the adverse pathology, in particular upper genital tract pathology 397 
in females. The holy grail is to produce a sterilizing vaccine that would completely 398 
prevent infection in the individual and hence also prevent transmission of infection to 399 
others. However, if 100% prevention of infection is not possible to achieve, then 400 
some consideration needs to be given to a vaccine that mainly prevents ascending 401 
infections that lead to disease pathology. In fact, one argument might be to focus on 402 
the disease pathology, as this is the major consequence of infection. A vaccine that 403 
could do both would clearly be ideal. The reality though is that any vaccine needs to 404 
be evaluated in clinical trials and the measurement of reduction of infection is more 405 
readily quantifiable than immune-mediated damage, such as PID or infertility. Until 406 
recently, the majority of efforts have focused on evaluating prototype vaccines by 407 
measuring the reduction in infectious burden following live challenge of vaccinated 408 
animals, almost totally in the mouse model. As already mentioned, these vaccines 409 
are much easier to evaluate through the regulatory process. Recently though, there 410 
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have been increasing and encouraging reports of vaccine strategies that can protect 411 
against the downstream adverse pathology [95].  412 
The other aspect of a C.trachomatis vaccine is the target group. All efforts to date 413 
have been directed at developing prophylactic vaccines, with the assumption that the 414 
vaccine would be administered to young girls prior to sexual activity. In reality though, 415 
a therapeutic vaccine that could be safely administered to women who either had a 416 
past or even current infection, would be very useful. There are very few published 417 
studies in this area, although the report of Carey et al. [86] in the C.muridarum –  418 
mouse model suggest that vaccinating either presently infected or previously 419 
infected individuals may not result in a strong immune response. 420 
Modelling the impact of a C.trachomatis STD vaccine 421 
There are no absolute criteria for the properties that a vaccine should have before it 422 
can be recommended for wide use in programs to improve the health of populations. 423 
The World Health Organization recommends vaccines which have long-term 424 
protection and high efficacy [89][100], however, vaccines which offer lower levels of 425 
protection are suggested for use in certain circumstances or populations [97-101]. 426 
When it is anticipated that only partially effective vaccines may become available, 427 
mathematical models have been used to investigate the potential epidemiological 428 
impact for the infectious disease in question, associated with different vaccine 429 
properties and implementation strategies [102]. Most theoretical vaccine modeling 430 
studies for sexually transmissible infections have been for HIV (e.g. [103-110]), but 431 
numerous vaccine modelling studies have emerged for HPV in recent years due to 432 
the availability and implementation of the cervical cancer vaccine in many countries 433 
[111-114]. These models have identified the most crucial vaccine parameters 434 
(vaccine take, efficacy and waning/duration) and demonstrated the trade-off between 435 
these factors and required frequencies and levels of boosting, coverage and intensity 436 
of scale-up among targeted population groups. It is particularly useful when 437 
comparison analyses across multiple models is done to produce a ‘consensus’ from 438 
the field (such as been attempted for aspects of HIV [115], HPV [114], and influenza 439 
[116] vaccine implementation).  440 
A comparison of Chlamydia screening models has been conducted [117] but 441 
currently there is only one modeling study that has assessed the potential impact 442 
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and critical properties associated with Chlamydia vaccines [118]. This analysis 443 
considered not only the public health outcomes of vaccine implementation but the 444 
measurable biological properties to be assessed in vaccine design and regulation. It 445 
found that in order to have the greatest public health impact, a vaccine should 446 
primarily aim to increase the threshold of the infectious dose required to infect 447 
susceptible individuals. The next most important objective would be to decrease the 448 
peak infectiousness among infected individuals. Both these parameters are regularly 449 
measured in vaccine trials (in the mouse model) and several vaccine antigens are 450 
showing promise in this regard. The duration of vaccine efficacy was also identified 451 
to be of large importance and would influence the coverage and boosting schedule 452 
required in implementation to achieve a desired epidemiological outcome. This is 453 
one aspect that has not yet been well addressed in vaccine trials. But an imperfect 454 
vaccine can still have an impact. For example, a vaccine which reduces the peak 455 
chlamydial load among infected individuals by just 1-log10 could reduce prevalence 456 
of Chlamydia in the population by 40-50% after 20 years.  In this respect, the models 457 
are very useful in that they give us an idea of just how effective a vaccine needs to 458 
be to (ie. what level of infectious load reduction) when translating mouse model data 459 
eventually across to human population studies.  460 
Future directions and opportunities 461 
While progress towards an effective C.trachomatis vaccine has been reasonably 462 
slow, it nevertheless has moved forward in a stepwise fashion, and there are some 463 
recent events that could significantly accelerate this goal. Whole organism vaccines 464 
(whether live or inactivated) do show a significant degree of protection, usually far 465 
beyond that obtained by individual purified antigen vaccines. Therefore, if we can 466 
avoid the deleterious pathology associated with these earlier versions, perhaps we 467 
can use this general approach. In this respect, the recent findings that the chlamydial 468 
plasmid contributes, by an as yet undefined mechanism, to the adverse pathology 469 
observed in both C.trachomatis and C.muridarum infections, could be a major 470 
opportunity [119]. A plasmid-free, attenuated strain of C.muridarum, while it grows 471 
similarly to the isogenic wild type, plasmid containing strain, fails to activate TLR 2-472 
independent immune responses and as a result, is attenuated during mouse genital 473 
tract infections and does not result in the upper genital tract pathology that is seen 474 
with the wild type strain [120]. The plasmid-deficient strain also functioned as a 475 
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successful live attenuated vaccine in mice, whereby infection (vaccination) with the 476 
plasmid-negative strain limited the pathology usually associated with subsequent 477 
infections [121]. Importantly, Kari et al. [80] showed a similar phenomenon with 478 
C.trachomatis, whereby they generated a plasmid-free, attenuated strain of ocular 479 
C.trachomatis and showed that it could protect against trachoma in a nonhuman 480 
primate model. These plasmid-free strains could be our best chance of a vaccine 481 
that can generate sufficiently strong immunity, involving both B and T cell responses, 482 
to an array of important antigens, in the absence of adverse pathology. Of course, 483 
the regulatory requirements involved with the use of live attenuated vaccines means 484 
that it will be essential to fully understand the molecular mechanisms underpinning 485 
these plasmid-free “vaccine” strains. In this respect, the other recent breakthrough 486 
that could significantly accelerate vaccine research is that we now have the ability to 487 
genetically manipulate Chlamydia [122]. This major achievement  that still has some 488 
technical challenges, means that potentially we can delete, or inactivate, key genes 489 
to understand their role in pathogenesis, and this should eventually result in a 490 
controlled means to produce a live attenuated vaccine strain that is unable to cause 491 
adverse pathology. These exciting advances, combined with rapid developments in 492 
vaccine adjuvants and delivery mechanisms, means that the previously elusive 493 
C.trachomatis vaccine goal may soon be within our reach.  494 
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Table 1: Chlamydia trachomatis antigens that stimulate host immune responses to 502 
genital tract infection 503 
Chlamydial antigen 
 
Immune response(s) elicited Reference(s) 
Polymorphic membrane protein D 
(pmpD) 
Genital tract Th1 cells and IgG2a mucosal 
antibodies 
Eko et al., 2011 
[123] 
Chlamydial type III-secreted 
effector protein (Tarp) 
Th1 dominant humoral and cellular responses Wang et al., 
2009 [124] 
Protein antigens CT823 and CT144 CD8+ T cell, Th1-polarised CD4+T cell,  
Th1-skewed antibody responses 
Picard et al., 
2012 [125] 
MOMP-based serovar E DNA 
vaccine 
Serum IgM, IgG and IgA, CD8+ and CD4+ Tcells 
in spleen and pelvic lymph nodes 
Schautteet et 
al., 2011 [126] 
C.trachomatis serovar D strain  
pgp3 gene 
Humoral (serum IgG) and mucosal IgA anti-
Pgp3 antibodies 
Comanducci et 
al, 1994 [127] 
Pgp4 gene Unknown - but  the mutant exhibited 
decreased expression levels of Pgp3, 
a potential virulence factor amongst others 
Song et al., 2013 
[55] 
TC0052, TC0189, TC0582, TC0660, 
TC0726, TC0816 and, TC0828 
IgG antibodies with both Th1 and Th2 bias Molina et al., 
2010 [128] 
MOMP (CT681), HtrA (CT823), 
OmcB (CT443), TARP (CT456), 
GroEL (CT110), Lcr-E (CT089),  
Nqr3 (TC0551/CT279), MAC-
perforin (TC0431/CT153), IncA 
(TC0396/CT119), and the 
hypothetical proteins  CT622, 
TC0284, TC0313, TC0651, TC0890, 
and TC0106 (CT016, CT043, CT372, 
CT601, and CT733). 
 
 
 
Human serum IgG,   
IFN-γ–producing CD4+ T cells 
 
 
 
Finco et al.,  
2011 [129] 
DnaK (CT396) Human CD4+ T cell responses Coler et al., 
2009 [130] 
CT043 CD4+ Th1 cells Meoni et al., 
2009 [131] 
OmcB (CT443)  
And also CT004, CT043, CT184, 
CT509, and CT611, CT082, 
CT089, CT322, CT396, and 
CT681, CT110 
 
 
T cells, B cells or both B and T cells (OmcB) 
 
 
Follman et al., 
2008 [132] 
Enolase (CT587) Human CD4+ T cells Goodall et al.,  
 [133] 
chlamydial protease-like activity 
factor (CPAF) 
CD4+T cell, IFN-y Murthy et al. 
2006 [134] 
NrdB  CD4+ T cells Barker et al.,  
2008 [135] 
Heat shock protein 60 (cHSP60) Cervical IgG and IgA antibodies, IFN-g Agrawal et al., 
2007 [136] 
Outer Membrane Protein 2 
(OMP2) 
Humoral antibody responses Portig et al., 
2003 [137] 
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 504 
Table 2 : Strategies for targeting antigens from various stages of the chlamydial 505 
developmental cycle 506 
Stage of the chlamydial 
developmental cycle 
Immune response needed 
/ possible 
Opportunities and 
challenges 
 
 
Initial attachment of the 
chlamydial EB to the new 
host cell 
 
 
Antibodies – should be 
neutralizing 
Has been the traditional 
approach for antigens 
such as MOMP. Vaccine 
needs to produce 
antibodies to 
conformational epitopes. 
Difficult to get 100% 
neutralization / blocking. 
Early alteration of host cell 
pathways to enable 
Chlamydia to successfully 
enter its inclusion and 
convert to the RB stage 
 
Primarily T cell response 
but antibodies may also be 
effective 
This phase has not been 
directly targeted although 
proteins such as TARP 
are involved. Many more 
targets are available for 
targeting. 
 
 
 
RB multiplication 
 
 
Primarily T cell response 
but antibodies may also be 
effective 
Many targets are available 
on / in the RB phase.  
Could an ineffective 
response to RB targets 
result in pushing the 
infected cell into 
persistence? 
 
 
 
Persistence phase 
 
 
Primarily T cell response 
but antibodies may also be 
effective 
This phase has not yet 
been specifically targeted.  
A multi-antigen vaccine 
consisting of acute and 
persistence phase targets 
could well have 
advantages. 
 
 
 
 
Late stage development 
and exit 
 
 
 
Primarily T cell response 
but antibodies may also be 
effective 
For Chlamydia to be 
“infectious” for its next 
host cell, it must transform 
from the RB stage to the 
EB stage, including all 
necessary surface 
displayed proteins. In 
addition to MOMP, other 
surface proteins are 
appealing targets.  
 507 
 508 
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 509 
Figure 1: Overview of the chlamydial developmental cycle, stages at which potential 510 
vaccine targets have, or could be, directed, and the immune pathways triggered 511 
during chlamydial infection. Panel A describes the seven key stages in the 512 
chlamydial developmental cycle; 1 – extracellular elementary bodies (EBs) and their 513 
initial attachment to susceptible cells; 2 – internalization of EBs inside suitable host 514 
cells and immediate subversion of host cell pathways; 3 – conversion of EBs to 515 
reticulate bodies (RBs) and further subversion of host cell pathways; 4 - 516 
multiplication of RBs via binary fission; 5 – persistent phase of chlamydial 517 
development in which the RBs are still metabolically active but have altered gene 518 
expression patterns and are less susceptible to host defences and antibiotics; 6 – 519 
conversion of RBs to EBs by an unknown trigger; 7 – exit of infectious EBs from the 520 
host cell.  521 
 522 
Panel B summarises the steps in the immune response (either following natural 523 
infection or immunisation), with a focus on the adaptive immune pathways. Red bold 524 
indicates components which have been experimentally confirmed for Chlamydia.  525 
Innate immune cells constitutively secrete an array of soluble antimicrobials including 526 
elafin, lysozyme and cathelicidins, amongst others. Chlamydial infection of columnar 527 
epithelial cells and local genital tract innate natural killer (NK) cells induces the 528 
production of interferon-g (IFN-g) and other pro-inflammatory cytokines and 529 
chemokines.  Recruitment and activation of B cell (Humoral) and T cell (Cell-530 
mediated/Adaptive) immunity is also coordinated by the release of these factors.  531 
Humoral immunity in the female genital tract is dominated by immunoglobulin (Ig) G 532 
although secretory IgA antibodies are also present at this mucosal site.  Once 533 
Chlamydia have established intracellular infection, cells of the adaptive immune 534 
system, and particularly T helper 1 (Th1) type CD4+ T cells secreting IFN-g are 535 
required for effective clearance of primary infection and to protect from re-infection. 536 
Other major lineages of activated CD4+ T cells that play critical roles in chlamydial 537 
infections include the Th2 cells, Th17 cells (producing IL-17 and IL-23) and 538 
Tregulatory (Treg) cells. Additional T cells involved in adaptive immunity include 539 
intraepithelial lymphocytes (γδ T cells) and cytotoxic T lymphocytes (CD8+ T cells) 540 
that are known to induce apoptosis of infected chlamydial cells. 541 
  542 
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